Answers are grounded in this paper and cite their sources.
Bauxite residue is one of the most important by-products from the alumina industry with no commercial use till now. The utilisation of bauxite residue through pelletising with different lime additions, hydrogen reduction, and smelting has been studied in this work. Three different types of green pellets were made with varying calcite-to-bauxite residue ratio and subsequently sintered at elevated temperatures. The sintered pellets were isothermally reduced at 1000°C under hydrogen gas followed by smelting of the reduced pellets in argon at 1500°C. Smelting of the reduced pellets leads to the recovery of metallic iron and the formation of a leachable calcium aluminate slag. X-ray diffraction (XRD) and scanning electron microscope (SEM) were used to characterise the phases and microstructural analysis. The iron produced in the smelting process has a high purity, above 99.5 wt per cent. While the iron content of the slags is quite low, and the slags shows variations of krotite (CaAl2O4), gehlenite (Ca2Al2SiO7), and perovskite (CaTiO3) phases based on the variation of calcite addition. It was found that the more calcite addition in pelletising yields higher percentage of krotite phase as compared to lower calcite-containing pellets. Employing quantitative XRD analysis, the krotite phase fraction was found approximately 85 wt per cent for higher calcite-added pellet, and around 74 wt per cent for lower calcite-added pellet. FactSage™, ver 8.1 (Thermfact and GGT- Technologies) thermodynamic software was used to evaluate the obtained experimental data, they both revealed that the components of the bauxite residue are mostly distributed into the calcium aluminate slag phase.
No takes yet. Share an insight, caveat, or question.
Kar et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: